Ignite Creation Date:
2025-12-24 @ 11:53 AM
Ignite Modification Date:
2026-07-04 @ 10:28 AM
Study NCT ID:
NCT02018861
Status:
COMPLETED
Last Update Posted:
2023-09-28
First Post:
2013-12-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Sponsor:
Incyte Corporation
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
INCB 50465-101 (CITADEL-101)
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None